Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942968 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
A Phase 4 study of Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT00942968: Completed Phase 4 study of Cancer, sponsored by Pfizer.
NCT00942968 is a Phase 4 study of Cancer that has completed, run by Pfizer. The registered enrollment target is 338 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00942968, a Phase 4 study of Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
Primary Outcome
A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: 1) bleeding accompanied by a decrease in hemoglobin of greater than or equal to (\>=) 2 gram per deciliter (g/dL), 2) bleeding occurred at a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial bleeding), 3) bleeding leads to a transfusion of two or more units of packed red blood cells, 4) bleeding leads to death. In this outcome measure, nu
Conditions Studied
Interventions
- DRUG dalteparin
Study Locations (20)
California
- Bay Area Cancer Research Group - Pleasant Hill
- Harbor-UCLA Medical Center - Torrance
Connecticut
- University of CT Health Center - Farmington
- Eastern Connecticut Hematology and Oncology Associates - Norwich
New York
- University of Rochester Medical Center - Rochester
- Stony Brook University, Medical Center - Stony Brook
Arizona
- Arizona Cancer Center - Tucson
District of Columbia
- Georgetown University Hospital-Lombardi Cancer Ctr - Washington D.C.
Florida
- Halifax Health - Daytona Beach
Georgia
- Atlanta Institute for Medical Research - Decatur
Illinois
- Orchard Healthcare Research Inc. - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
What the finished NCT00942968 record still lists
NCT00942968 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which dalteparin is the first listed.
NCT00942968 names 20 study sites across 17 states, led by California, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT00942968 about?
NCT00942968 is a clinical study titled "Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer". The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
What is the current status of trial NCT00942968?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 338 participants. The study started on 2009-06. Estimated completion is 2013-06.
What conditions does trial NCT00942968 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00942968?
The interventions under investigation include: dalteparin (DRUG).
Who is sponsoring clinical trial NCT00942968?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00942968 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00942968's enrollment target sits among peer trials
338 169th of 615 higher than 447 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Tobacco Treatment Comparison for Cancer Care
COMPLETED · Phase 4
-
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia